Collection and Data Analysis Methodology

The Working Group has employed a standardized methodology since 2004 to generate comprehensive statistics on investment in HIV prevention research and development, including disaggregated trends. These methods were employed to generate the estimates of funding for R&D presented in this report. Categories used to describe different R&D activities were derived from those developed by the US NIH and are shown on the website. A set of questions on COVID-19 were specially added in response to ongoing impacts of the pandemic in 2020 and 2021. 

Data Collection Categories

  • Preventive HIV vaccines 
  • Microbicides 
  • Multipurpose prevention technologies
  • Pre-exposure Prophylaxis (PrEP)
  • Treatment as prevention (TasP)
  • Male circumcision 
  • Female condom
  • Prevention of mother-to-child transmission (PMTCT)
  • HIV cure
  • Therapeutic AIDS vaccines